Johnson & Johnson said it was negotiating partnership deals with two Chinese companies as it taps into a biotech boom in the country driven by a surge in private investment and government support, according to a senior executive.
据一位高管透露，强生(Johnson & Johnson)正与两家manbetx3.0 公司谈判合作协议。这家美国制药商正寻求利用manbetx3.0 生物技术领域在私人投资激增和政府支持下出现的繁荣。
您已阅读5%（312字），剩余95%（6230字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。